Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study

Abstract Background Relapse and refractory (R/R) rates after first‐line R‐CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively. Aims We conducted a retrospective real‐world analysis aimed at evaluating clinical outcomes of R/R DLBCL patients. Material and Methods Overall, 40...

Full description

Saved in:
Bibliographic Details
Main Authors: Irene Dogliotti, Veronica Peri, Michele Clerico, Francesco Vassallo, Davide Musto, Silvio Mercadante, Simone Ragaini, Barbara Botto, Mario Levis, Mattia Novo, Marco Ghislieri, Luca Molinaro, Umberto Mortara, Chiara Consoli, Alessio Lonardo, Giulia Bondielli, Simone Ferrero, Roberto Freilone, Umberto Ricardi, Benedetto Bruno, Federica Cavallo
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Cancer Medicine
Subjects:
chemotherapy
diffuse large B cell lymphoma
real world
refractory disease
relapse
rituximab
Online Access:https://doi.org/10.1002/cam4.7448
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.7448

Similar Items